Patents Examined by Lawrence E. Crane
  • Maintenance of platelet inhibition during antiplatelet therapy
    Patent number: 10231987
    Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: March 19, 2019
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
  • Isotopologues of 5-azacytidine
    Patent number: 10220050
    Abstract: The present disclosure provides isotopologues of 5-azacytidine.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 5, 2019
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Cell-permeable probes for identification and imaging of sialidases
    Patent number: 10214765
    Abstract: Provided herein are compounds for use as sialidase inhibitors, including alkynyl-3-fluorosialyl fluoride. The compounds, which include the compound DFSA, function by trapping a 3-fluorosialylenzyme intermediate (reporter-inhibitor-enzyme conjugate). These compounds can be conjugated with a detectable tagging moiety for isolation and identification of sialidases.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 26, 2019
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Jim-Min Fang, Yih-Shyun E. Cheng, Chamg-Sheng Tsai
  • Method for purifying reduced form of ?-nicotinamide adenine dinucleotide
    Patent number: 10214556
    Abstract: A method for purifying a salt of reduced form of ?-nicotinamide adenine dinucleotide (NADH) includes: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction, collecting a concentrate for use; adding an ion pair reagent to the concentrate, and purifying by gradient elution to obtain a purified filtrate using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; changing the cations in the purified filtrate into sodium ions to obtain a filtrate by using a cation exchange resin; and nanofiltrating the filtrate, and freeze drying in a vacuum freeze drier. The method results in an excellent purity and yield of a salt of NADH that meets requirements in industry.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 26, 2019
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Zhu Dai, Qi Zhang
  • Method for purifying beta-nicotinamide mononucleotide
    Patent number: 10214552
    Abstract: A method for purifying ?-nicotinamide mononucleotide (NMN) includes: sequentially microfiltrating and nanofiltrating a crude product solution containing NMN using membrane concentration devices to obtain a concentrated crude product solution; adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B, to obtain a purified sample solution; concentrating the purified sample solution by nanofiltration and freeze drying in a vacuum freeze drier to obtain a purified NMN.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: February 26, 2019
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD.
    Inventors: Rongzhao Fu, Zhu Dai, Qi Zhang
  • Method for liquid-phase synthesis of nucleic acid
    Patent number: 10214555
    Abstract: In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R1, Y, Base, Z, Ar, R2, R3 and n are each as defined in Claim 1]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method cars dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3?-direction but also in the 5?-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: February 26, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITJED
    Inventors: Mitsuru Nonogawa, Toshiaki Nagata, Hideki Saito, Tsuneo Yasuma
  • Compositions of selenoorganic compounds and methods of use thereof
    Patent number: 10201558
    Abstract: The present application relates to compositions comprising selenium compounds, such as 5?-Methylselenoadenosine, a compound of Formula (I), and combinations thereof, and methods of using the same for inhibiting ? amyloid aggregation, ApoE4 expression, p38 or Tau protein phosphorylation, or increasing Neprilysin and Insulin Degrading Enzyme expression.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 12, 2019
    Assignee: Alltech, Inc.
    Inventors: Ronan Power, Zi-Jian Lan
  • Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling
    Patent number: 10189873
    Abstract: The invention provides compounds of the purine cyclic dinucleotide (CDN) class, useful as inhibitors of the STING (Stimulator of Interferon Genes) pathway, and methods of their administration to individuals in need thereof.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 29, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne
  • Biodegradable control of bacterial cellulose by radiation technology and absorbable periodontal material using same
    Patent number: 10130653
    Abstract: An absorbable periodontal tissue and bone regeneration material uses bacterial cellulose that has been exposed to radiation. The bacterial cellulose was confirmed to block the invasion of soft tissue in a calvarial defect in rat and rabbit models and to display excellent absorptiveness enough to contribute bone formation. Therefore, the bacterial cellulose can be developed as an absorbable periodontal tissue and bone regeneration material useful in the field of medical engineering by regulating biodegradability without using chemicals that are toxic to human and environment.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: November 20, 2018
    Assignee: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Youn-Mook Lim, Sung In Jeong, Hui-Jeong Gwon, Jong Seok Park, Jung-Bo Huh
  • Methods and compositions for treating pain
    Patent number: 10117890
    Abstract: Methods for treating pain such as fibromyalgia, comprising administering to a subject in need thereof an effective amount of an adenosine analog, wherein the adenosine analog may be a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the adenosine analog for use in treating pain (e.g., fibromyalgia), optionally further comprising Substance P (SP), are also provided.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 6, 2018
    Assignee: Academia Sinica
    Inventors: Chih-Cheng Chen, Yun-Lian Lin, Jim-Min Fang, Yijuang Chern, Chia-Ching John Lin, Wei-Nan Chen, Chun-Jung Lin
  • Polynucleotide capture materials, and methods of using same
    Patent number: 10100302
    Abstract: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 16, 2018
    Assignee: HANDYLAB, INC.
    Inventors: Sundaresh N. Brahmasandra, Elizabeth Craig
  • Phosphoramidite building blocks for sugar-conjugated oligonucleotides
    Patent number: 10087208
    Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 2, 2018
    Assignee: AM CHEMICALS LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy
  • Compositions and methods for nucleic acid extraction
    Patent number: 10072259
    Abstract: Compositions and techniques for the extraction, enrichment and isolation of nucleic acids from yeast in a whole blood sample using amine monomers are disclosed herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 11, 2018
    Assignee: Abbott Molecular Inc.
    Inventor: Gerard J. Gundling
  • Reducing or non-reducing polynucleotide polymer for drug delivery and method for preparing same
    Patent number: 10071055
    Abstract: The present invention relates to a reducing or non-reducing polynucleotide polymer using a nucleotide from AMP, ADP, ATP, GMP, GDP, GTP, CMP, CDP and CTP, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and N-hydroxy-succinimide (NHS) for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 11, 2018
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Han Chang Kang, You Han Bae, Ha Na Cho
  • Maintenance of platelet inhibition during antiplatelet therapy
    Patent number: 10022391
    Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
    Type: Grant
    Filed: April 24, 2016
    Date of Patent: July 17, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
  • Oligomer-conjugate complexes and their use
    Patent number: 10023861
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: July 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Process for preparing nucleoside prodrugs
    Patent number: 10005810
    Abstract: Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of the compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 26, 2018
    Assignee: University College Cardiff Consultants Limited
    Inventors: Chirstopher McGuigan, Fabrizio Pertusati
  • Substituted gemcitabine bicyclic amide analogs and treatment methods using same
    Patent number: 10000521
    Abstract: In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 19, 2018
    Assignee: Nucorion Pharmaceuticals, Inc.
    Inventors: Zucai Suo, Vinod P. Vyavhare, David J. Taggart
  • Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
    Patent number: 9994604
    Abstract: The present invention relates to pyrazolotriazolyl nucleoside analogs, such as oligonucleotide comprising them, and uses in treatment of hepatitis C virus infections. Further the invention relates to a method for reducing gene expression in a cell comprising transfecting the cell with such an oligonucleotide.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 12, 2018
    Assignee: Bio-Lab Ltd.
    Inventors: Jean-Christophe Truffert, Myriam Lefoix, Jean Hildesheim, Tirtsa Kleinman
  • Non-natural nucleosides as theranostic agents
    Patent number: 9988680
    Abstract: A composition for monitoring DNA damage includes a 3-ethynyl-5-nitroindolyl-2?-deoxyribose compound or pharmaceutically acceptable salt thereof and a detectable moiety with a click-reactive functional group that is complementary to the alkyne group of the compound.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee, Edward Motea